Market Cap 7.84B
Revenue (ttm) 739.02M
Net Income (ttm) -436.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -59.05%
Debt to Equity Ratio -3.65
Volume 1,996,900
Avg Vol 2,793,294
Day's Range N/A - N/A
Shares Out 124.71M
Stochastic %K 82%
Beta 1.53
Analysts Strong Sell
Price Target $68.09

Company Profile

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-pow...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 855 698 8887
Fax: 888 974 4258
Address:
3100 Hanover Street, Palo Alto, United States
THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Oct. 6 at 3:21 PM
1 · Reply
SweepCastApp
SweepCastApp Oct. 4 at 6:28 AM
$GH: Unusual Options Activity Alerted CALL flow observed 180x contracts at Strike price of $60 Exp on 10/17/2025 with Premium of $73K and showing BEARISH Sentiment
0 · Reply
IN0V8
IN0V8 Oct. 3 at 4:41 PM
$GH Opportunity Barclays raises target price to $70 from $60
0 · Reply
healthcareguru
healthcareguru Oct. 3 at 3:23 PM
$GRAL short the trash…MCED is the future, but their test is inferior, $GH & $EXAS will crush them, and they’re hemorrhaging cash…more dilution is coming near-term. Back to <$50. 👎🐺
1 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 2:04 PM
Barclays has adjusted their stance on Guardant Health ( $GH ), setting the rating to Overweight with a target price of 60 → 70.
0 · Reply
SweepCastApp
SweepCastApp Oct. 1 at 10:24 PM
$GH: Unusual Options Activity Alerted CALL flow observed 250x contracts at Strike price of $60 Exp on 10/17/2025 with Premium of $105K and showing BEARISH Sentiment
0 · Reply
IN0V8
IN0V8 Sep. 29 at 6:18 PM
$GH Opportunity Jefferies raises target price to $75 from $60
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Sep. 29 at 3:18 PM
0 · Reply
Gator5326
Gator5326 Sep. 29 at 1:05 PM
$GH Keeps getting better and better 😎 FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company’s Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer
0 · Reply
Gator5326
Gator5326 Sep. 29 at 12:51 PM
$GH https://u18966101.ct.sendgrid.net/ls/click?upn=u001.4ITdg8fiPHHXRRODKhpNknNKs0V2h8ItR6Q2oQCQKcTyRrxC8ZerlixSyXRNZh4ketL7E2RWkAerRsZCr7TPZ-2FtX741n0Z6WOyiD4GHhsE36ctACQl7uWssbAln3fW2uWhJD5lZhqTv-2F9MEZMl7r8DYlBlMifaFHVTqpVeNRX0TbHY72WaR6pIt9vAmki-2Fmx4OlrBaIiQbXFMBiPEApqivYOVulQzSYYFRbgLjnqe6OlvgiUeAnNA7Y8ajGAFaPN10EvoIM8Xqtf1z7IQVkauMzQ43ZGb-2FFntVti6CA9dIiHGy12-2B0Sv-2FSw-2FhEWjdrGYN7P2tqfCDE0tiyAQaOGz9Q-3D-3DQova_n7gaS9t6bMxECCQWPRdwdqPZyOAjF4RSivuNxLLPR-2FSmysoqQW1ClVyewMaUHyr5PXnLg-2BfGbSor9w1GLElWTiEw3tZro1MLP1IzWdS5qPpbfYGAtnJcrhAqCrHeCZaHk1HJi3Qh0rv9eeTGH71QjD0X5C03hOrj11jLeTHJq9vbXHc0ATVC8u6QncnKMon8qisX3xT2y5dYuYtSt1veB-2FcY7Y-2BhwnRugCE5yXv7t8-2BPdzlz9Ag4nBAXe9WE4-2BU-2BR5gYH5L45rCwVXtd7utJuV9wsbhMs7tUaVvc1P3yEkXZu3-2Ban1vWSnF6pv-2B8lk1Ued-2Bks8PFcFOjDqcduVIcnr5MymzV9XWCvBOvEFSahkbrDTpYnsln2oLT-2FWJP8QUQNn89oCliJYclQH-2FFq0G7XOv8Imas5-2FGqNYZK7hmfqirBlpC2HBYvjlv7vcayA4hLEMX1VpZw6wyFnNSzUUnjSWdluyRdJUQ4f7HzGKqZx4w-2FZoW3-2FteLSY-2FEKX01OkMBdta7VwYFuk94FL5X-2BShE-2Bg-3D-3D
0 · Reply
Latest News on GH
Guardant Health, Inc. (GH) Analyst/Investor Day Transcript

Sep 24, 2025, 7:17 PM EDT - 12 days ago

Guardant Health, Inc. (GH) Analyst/Investor Day Transcript


Alex M. Azar II Joins Guardant Health Board of Directors

Sep 15, 2025, 4:07 PM EDT - 21 days ago

Alex M. Azar II Joins Guardant Health Board of Directors


Guardant Health to Host Investor Day on September 24, 2025

Aug 28, 2025, 4:05 PM EDT - 5 weeks ago

Guardant Health to Host Investor Day on September 24, 2025


Guardant Health, Inc. (GH) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 11:13 AM EDT - 2 months ago

Guardant Health, Inc. (GH) Q2 2025 Earnings Call Transcript


Guardant Health to Participate in Upcoming Investor Conferences

May 8, 2025, 4:05 PM EDT - 5 months ago

Guardant Health to Participate in Upcoming Investor Conferences


Guardant Health, Inc. (GH) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 10:25 PM EDT - 5 months ago

Guardant Health, Inc. (GH) Q1 2025 Earnings Call Transcript


THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Oct. 6 at 3:21 PM
1 · Reply
SweepCastApp
SweepCastApp Oct. 4 at 6:28 AM
$GH: Unusual Options Activity Alerted CALL flow observed 180x contracts at Strike price of $60 Exp on 10/17/2025 with Premium of $73K and showing BEARISH Sentiment
0 · Reply
IN0V8
IN0V8 Oct. 3 at 4:41 PM
$GH Opportunity Barclays raises target price to $70 from $60
0 · Reply
healthcareguru
healthcareguru Oct. 3 at 3:23 PM
$GRAL short the trash…MCED is the future, but their test is inferior, $GH & $EXAS will crush them, and they’re hemorrhaging cash…more dilution is coming near-term. Back to <$50. 👎🐺
1 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 2:04 PM
Barclays has adjusted their stance on Guardant Health ( $GH ), setting the rating to Overweight with a target price of 60 → 70.
0 · Reply
SweepCastApp
SweepCastApp Oct. 1 at 10:24 PM
$GH: Unusual Options Activity Alerted CALL flow observed 250x contracts at Strike price of $60 Exp on 10/17/2025 with Premium of $105K and showing BEARISH Sentiment
0 · Reply
IN0V8
IN0V8 Sep. 29 at 6:18 PM
$GH Opportunity Jefferies raises target price to $75 from $60
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Sep. 29 at 3:18 PM
0 · Reply
Gator5326
Gator5326 Sep. 29 at 1:05 PM
$GH Keeps getting better and better 😎 FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company’s Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer
0 · Reply
Gator5326
Gator5326 Sep. 29 at 12:51 PM
$GH https://u18966101.ct.sendgrid.net/ls/click?upn=u001.4ITdg8fiPHHXRRODKhpNknNKs0V2h8ItR6Q2oQCQKcTyRrxC8ZerlixSyXRNZh4ketL7E2RWkAerRsZCr7TPZ-2FtX741n0Z6WOyiD4GHhsE36ctACQl7uWssbAln3fW2uWhJD5lZhqTv-2F9MEZMl7r8DYlBlMifaFHVTqpVeNRX0TbHY72WaR6pIt9vAmki-2Fmx4OlrBaIiQbXFMBiPEApqivYOVulQzSYYFRbgLjnqe6OlvgiUeAnNA7Y8ajGAFaPN10EvoIM8Xqtf1z7IQVkauMzQ43ZGb-2FFntVti6CA9dIiHGy12-2B0Sv-2FSw-2FhEWjdrGYN7P2tqfCDE0tiyAQaOGz9Q-3D-3DQova_n7gaS9t6bMxECCQWPRdwdqPZyOAjF4RSivuNxLLPR-2FSmysoqQW1ClVyewMaUHyr5PXnLg-2BfGbSor9w1GLElWTiEw3tZro1MLP1IzWdS5qPpbfYGAtnJcrhAqCrHeCZaHk1HJi3Qh0rv9eeTGH71QjD0X5C03hOrj11jLeTHJq9vbXHc0ATVC8u6QncnKMon8qisX3xT2y5dYuYtSt1veB-2FcY7Y-2BhwnRugCE5yXv7t8-2BPdzlz9Ag4nBAXe9WE4-2BU-2BR5gYH5L45rCwVXtd7utJuV9wsbhMs7tUaVvc1P3yEkXZu3-2Ban1vWSnF6pv-2B8lk1Ued-2Bks8PFcFOjDqcduVIcnr5MymzV9XWCvBOvEFSahkbrDTpYnsln2oLT-2FWJP8QUQNn89oCliJYclQH-2FFq0G7XOv8Imas5-2FGqNYZK7hmfqirBlpC2HBYvjlv7vcayA4hLEMX1VpZw6wyFnNSzUUnjSWdluyRdJUQ4f7HzGKqZx4w-2FZoW3-2FteLSY-2FEKX01OkMBdta7VwYFuk94FL5X-2BShE-2Bg-3D-3D
0 · Reply
G101SPM
G101SPM Sep. 29 at 12:25 PM
$GH $60.88 bid. HOLDING LONG POSITION BRIEF: Guardant Health: FDA approves Guardant360 CDx as companion diagnostic for Eli Lilly's (LLY) Inluriyo for treatment of ESR1-mutated advanced breast cancer.
0 · Reply
SweepCastApp
SweepCastApp Sep. 28 at 5:50 PM
$GH: Unusual Options Activity Alerted CALL flow observed 162x contracts at Strike price of $60 Exp on 01/16/2026 with Premium of $130K and showing BEARISH Sentiment
0 · Reply
topstockalerts
topstockalerts Sep. 26 at 5:02 PM
Guardant Health will launch its Shield multi-cancer blood test next month, aiming to detect various cancers early using AI. The company expects the test’s market could expand to $300 billion by identifying early signals for hundreds of diseases beyond cancer. It also anticipates achieving free-cash-flow positivity by 2028, with annual revenue growing 34% to $2.2 billion. Shield, already FDA-approved for early colorectal cancer detection, will allow doctors and patients to receive results for additional cancers starting in October. Pricing is expected to fall below $1,000, with Medicare reimbursing $1,500, potentially driving sales above $500 million by 2028. Guardant leverages AI and a biobank of over one million cancer cases to expand detection beyond cancer to organs including the brain, heart, lungs, and liver. Analysts see potential annual sales of $50 billion if cancers are caught early. $GH $EXAS $GRAL
0 · Reply
JarvisFlow
JarvisFlow Sep. 26 at 11:42 AM
Canaccord Genuity has adjusted their stance on Guardant Health ( $GH ), setting the rating to Buy with a target price of 65 → 75.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 26 at 10:04 AM
Enter: $GH OCT 17 2025 $60 CALLS Buy in Price: $2.25 - $2.30 Take Profit: $4.57 Stop Bleeding: $1.98 ROI Potential: 103% Exit Within: 313 Minutes https://moneygroup.us/alerts
0 · Reply
NJ125
NJ125 Sep. 26 at 8:04 AM
$GH Canaccord out today with a massive 31 page deep dive report following GH Investor Day in Manhattan. Moves 12 month target price up to $75.
0 · Reply
JarvisFlow
JarvisFlow Sep. 25 at 5:52 PM
TD Cowen updates rating for Guardant Health ( $GH ) to Buy, target set at 63 → 72.
0 · Reply
JarvisFlow
JarvisFlow Sep. 25 at 3:47 PM
Wolfe Research has updated their rating for Guardant Health ( $GH ) to Outperform with a price target of 75.
0 · Reply
TrendEdgeLogan
TrendEdgeLogan Sep. 25 at 3:41 PM
$GH Shake and bake, see the weekly close
0 · Reply
G101SPM
G101SPM Sep. 25 at 2:33 PM
$GH $62.04 +4.37 bid. SELL/TAKE PROFIT of 10% of net position. DAC (dollar average cost doesn't included adjustment to net profit of this SELL). EXIT $85.00. https://stocktwits.com/G101SPM/message/627987915 note: SELL instigated by today's 70% cash reserve suggestion.
0 · Reply
Sillyspuh
Sillyspuh Sep. 25 at 2:32 PM
$GH Nice recovery
0 · Reply
ProtectThisHouse
ProtectThisHouse Sep. 25 at 2:24 PM
$GH May get there even sooner!
0 · Reply